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Abstract: Trehalose is a naturally occurring disaccharide comprised of two molecules of 
glucose. The sugar is widespread in many species of plants and animals, where its function 
appears to be to protect cells against desiccation, but is not found in mammals. Trehalose has 
the ability to protect cellular membranes and labile proteins against damage and denaturation 
as a result of desiccation and oxidative stress. Trehalose appears to be the most effective sugar 
for protection against desiccation. Although the exact mechanism by which trehalose protects 
labile macromolecules and lipid membranes is unknown, credible hypotheses do exist. As well 
as being used in large quantities in the food industry, trehalose is used in the biopharmaceutical 
preservation of labile protein drugs and in the cryopreservation of human cells. Trehalose is 
under investigation for a number of medical applications, including the treatment of   Huntington’s 
chorea and Alzheimer’s disease. Recent studies have shown that trehalose can also prevent 
damage to mammalian eyes caused by desiccation and oxidative insult. These unique properties 
of trehalose have thus prompted its investigation as a component in treatment for dry eye 
syndrome. This interesting and unique disaccharide appears to have properties which may be 
exploited in ophthalmology and other disease states.
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Introduction
Trehalose, a naturally occurring alpha-linked disaccharide formed of two molecules of 
glucose (Figure 1), was isolated in the mid 19th century by the French chemist, Marcellin 
Berthelot, from Trehala manna, a sweet substance obtained from the nests and cocoons 
of the Syrian coleopterous insect (Larinus maculatus, Larinus nidificans) which feeds on 
the foliage of a variety of thistles. It has been used as a foodstuff, and is also called “nest 
sugar”. In the intervening years, there has been considerable research on the biological 
and chemical properties of trehalose and on its role in   living   organisms. A recent PubMed 
search yielded more than 4600 references for the search term “trehalose”, including com-
prehensive reviews of the biology of trehalose in plants, insects, and other species.1–3
Trehalose has found a number of practical and commercial applications, particularly in 
the food and cosmetic industries2 and as an excipient in pharmaceutical formulations, and 
is prepared in bulk quantities by enzymatic conversion of starch, primarily in Japan.
Function of trehalose in trehalose-producing 
organisms
One of the most intriguing characteristics of trehalose is that it is synthesized by many 
living organisms, including insects, plants, fungi, and micro-organisms,3 as a response Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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to prolonged periods of desiccation. This very useful prop-
erty, known as anhydrobiosis, confers on an organism the 
ability to survive almost complete dehydration for prolonged 
periods and subsequently reanimate. In many species, such 
anhydrobiosis is believed to be due to the interaction between 
trehalose, water, and cell structures that permit survival of 
the organism during periods of desiccation. Trehalose is not 
synthesized by mammals.
Trehalose and protection  
from dehydration
A “water replacement” hypothesis to explain the role of 
trehalose in anhydrobiosis has been proposed. This hypoth-
esis suggests that trehalose replaces water in the desiccated 
organism by hydrogen bonding interactions with polar groups 
on membrane lipids and proteins.4,5
An alternative hypothesis has suggested that trehalose 
modifies the tetrahedral hydrogen-bond structure of water and 
rearranges the remaining water molecules around biological 
structures. This reduces the amount of water at the interface 
of biomacromolecules and membranes, in turn avoiding struc-
tural fluctuations and damage to cellular organelles during 
dehydration.6 In addition, some physical chemistry properties 
of trehalose in more concentrated solution are particularly 
beneficial during desiccation; on drying it has a lower ten-
dency to form crystals that can damage cell organelles than 
other disaccharides, but instead is thought to form a gel phase 
that might contribute to resilience to cellular desiccation.7
Trehalose and membrane  
lipid bilayers
Lipid (more correctly phospholipid) bilayers are essential 
components of cells. As well as forming a physical bar-
rier between the contents of the cell and its environment, 
key intracellular organelles are formed from lipid bilayers. 
A degree of hydration is essential for the integrity of lipid 
bilayers. Desiccation causes irreversible damage to the 
integrity of the cell and, in particular, results in lipid phase 
transition, a change that trehalose has been shown to inhibit. 
Trehalose thus maintains the lipid in the liquid phase in 
the absence of water.8 It has been shown that stabilization 
of lipid systems with trehalose enables the membranes to 
retain both their functional properties (eg, calcium transport, 
ATPase activity) and cellular contents.9 In the great major-
ity of   studies, trehalose is the most effective saccharide for 
maintaining the integrity of phospholipid bilayers.4
Trehalose and labile proteins
Trehalose also preserves labile cellular proteins against desic-
cation, probably by interacting directly with the dehydrated 
protein via hydrogen bonding between its hydroxyl groups and 
polar residues in the protein. Trehalose is an important protector 
of protein integrity, by limiting protein denaturation under heat 
stress, oxidant injury, and anoxia,10 and is the most effective 
disaccharide for stabilizing proteins during desiccation.4 The 
various theories to explain the exceptional properties of treha-
lose in stabilizing proteins have been recently reviewed.11
The ability of trehalose to stabilize fragile proteins 
and protect them from denaturation has been exploited in 
biopharmaceutical formulations, notably monoclonal anti-
bodies, including ranibizumab and bevacizumab which are 
formulated in solution, or trastuzumab which is subjected to 
freeze-drying. The ability of trehalose to stabilize aggregation-
prone protein molecules is under investigation as a possible 
approach in the treatment of polyglutamine diseases, such as 
Huntington’s chorea12,13 and Alzheimer’s disease.14,15
Trehalose and oxygen radicals
The evidence thus far suggests that trehalose can protect against 
desiccation, both in lower organisms and also in mammalian 
cells. In addition, evidence is accumulating that trehalose has a 
role to play in protecting cells against oxidative stress. A new 
role for trehalose in protecting cells against oxygen radicals 
has been postulated. Yeast cells exposed to mild heat shock 
or proteasome inhibitors respond with an accumulation of 
trehalose, coincident with a marked increase in viability, when 
exposed to a free radical-generating system. Moreover, this 
improvement in cellular viability is absent in mutant strains 
of yeast cells that lack the capability to synthesize trehalose. 
These findings suggest that trehalose has a role in protecting 
cells and their components from oxidative damage.16
When oxidative stress was provoked in yeast cells by the 
application of menadione, a source of superoxide, cell survival 
was markedly improved by pretreatment with trehalose or 
by heat treatment, which increases trehalose   accumulation.17 
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Figure 1 Structure of trehalose. Registry number: 99-20-7; Molar mass: 342.296 g/mol 
(anhydrous);  378.33  g/mol  (dihydrate);  molecular  structure:  α-D-glucopyranosyl 
α-D-glucopyranoside (α,α-trehalose).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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The improvement in cell survival was   apparently correlated 
with reduced lipid peroxidation. Therefore, it would appear 
that the role of trehalose is to protect cells, and lipid bilayers 
in particular, from oxidative damage.
Effects of trehalose in mammalian 
cells
Whilst convincing evidence indicates that accumulation of 
trehalose in the cytoplasm of many lower organisms func-
tions to protect proteins and membranes from denaturation 
caused by desiccation, heat, and oxidative stress,8 mammalian 
cells do not have the ability to synthesize trehalose, although 
humans can metabolize ingested trehalose as a result of the 
trehalase enzyme in the intestinal villi.
The ability of trehalose to stabilize membranes and   proteins 
has obviously raised interest in the potential protective effects 
of trehalose when administered to mammalian cells. For 
  example, trehalose has been investigated in the   cryopreservation 
of human hepatocytes for cell   transplantation.18   Supplementation 
of standard cryopreservation solution with trehalose significantly 
improved post-thaw cell viability, metabolism, and plating 
efficiency, suggesting that trehalose makes a useful contribu-
tion to hepatocyte   cryopreservation. Similarly, when introduced 
into human oocytes by microinjection, trehalose was shown 
to confer significant protection to the oocyte cells against the 
stresses associated with freezing. Indeed, whilst the majority of 
trehalose-treated cells survived freezing to -60°C, none of the 
untreated cells survived this temperature.19
Protective effects of trehalose  
on desiccated epithelial cells
Trehalose protects desiccated cultured corneal cells from 
death. Following preincubation with various concentrations 
of trehalose or a control medium, cultured human corneal 
cells were left to dry for 30 minutes. The percentage of dead 
cells was markedly and significantly lower in cells preincu-
bated with trehalose than in those preincubated in a control 
  medium.20 This finding was confirmed in an analogous ex vivo 
study carried out in enucleated porcine eyes. Following incu-
bation with maltose, sucrose, trehalose, or saline, the corneal 
epithelial surfaces were allowed to dry. The tissue incubated 
with trehalose was visibly smoother under   dissecting micro-
scopic observation, and there were significantly fewer pits 
observed under atomic force microscopy.21
Trehalose in ophthalmology
As the two above mentioned laboratory studies convincingly 
show, trehalose can confer desiccation tolerance to   mammalian 
corneal cells, just as it does to cells of lower organisms. 
  Therefore, it was interesting to investigate whether such a 
protective effect could also be demonstrated in vivo. This was 
evaluated in an experimental model of murine dry eye.22 Briefly, 
mice were exposed to controlled low-humidity airflow and tem-
perature for 21 days. This resulted in a severe evaporative dry 
eye syndrome displaying biological and morphologic changes 
similar to those in humans. This dry eye environment appears to 
upregulate apoptosis on the ocular surface.   Following exposure 
to the evaporative environment, the mice were randomized to 
receive topical administration of 30 mg/mL trehalose ophthal-
mic solution (Thealoz®, Laboratoires Théa, Clermont-Ferrand, 
France) or a phosphate-buffered saline control solution during 
a further 14 days’ exposure to the evaporative environment. 
Trehalose administration resulted in significant improvements 
on the ocular surface (cornea and conjunctiva), including 
reduction of corneal fluorescein staining area, decrease of ruf-
fling and desquamating cells on the apical corneal epithelium, 
as well as a decrease in the number of apoptotic cells in the 
ocular surface epithelium when compared with controls, an 
effect comparable with that obtained in homologous mouse 
blood serum (Figure 2).23
In a subsequent and as yet unpublished study using this 
same model of dry eye, the same investigators compared 
topical trehalose with topical cyclosporin 0.05% ophthalmic 
solution.24 Consistent with previous reports,25 topical 
cyclosporin significantly reduced epithelial apoptosis on 
the ocular surface and protected against goblet cell loss 
in this experimental murine model of keratoconjunctivitis 
sicca.   Trehalose produced some of the same responses as 
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Figure 2 Trehalose protects against corneal damage due to desiccation. Corneal 
fluorescein  staining  following  exposure  to  a  desiccant  environment.  Mice  were 
exposed to a desiccating environment for 21 days and then received treatment 
with phosphate-buffered saline, trehalose eyedrops, or mouse serum eyedrops for 
14 days. A) Control mice, B) 21 days desiccation without treatments, C) and D) 
seven and 14 days’ desiccation with trehalose treatment, E) and F) seven and 14 days 
desiccation’ with mouse serum treatment, G) and H) seven and 14 days’ desiccation 
with phosphate-buffered saline treatment. 
Copyright© 2010. elsevier. Reproduced with permission from Chen w, Zhang X, 
Liu M, et al. Trehalose protects against ocular surface disorders in experimental 
murine  dry  eye  through  suppression  of  apoptosis.  Exp  Eye  Res.  2009;89: 
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cyclosporin upon topical application and maintained corneal 
health, but was also more effective than cyclosporin at 
reducing epithelial apoptosis on the ocular surface. Topical 
cyclosporin significantly reduced the number of active CD4-
positive T cells, while trehalose had no such effect, suggesting 
that the mechanism of trehalose in this model is more that of a 
surface protectant than of a pharmacological agent. Additional 
experiments are ongoing for trehalose in the murine dry eye 
model to determine its effects on desiccating stress at the 
corneal barrier and the expression of metalloproteinases.26
The damage done to corneal tissue by ultraviolet B irra-
diation occurs via an oxidative pathway in which corneal 
antioxidants, which protect the cornea from highly reactive 
oxygen and nitrogen species, are depleted. Therefore, the 
potential protective effect of trehalose in rabbit eyes submitted 
to ultraviolet B rays has been investigated.27 During irradiation 
with ultraviolet B at a daily dose equivalent to five hours of 
exposure of the human cornea to ultraviolet B from sunlight, 
trehalose was applied as 30 mg/mL eye drops to the right eye 
while buffered saline was applied to the left eye. In trehalose-
treated eyes, there was less corneal edema (corneas were more 
transparent), and much less intracorneal inflammatory cell 
infiltration, and neovascularization was suppressed (Figure 3). 
Expression of nitric oxide synthases leading to the formation of 
nitric oxide was reduced and formation of cytotoxic peroxyni-
trite decreased. Aldehyde dehydrogenase 3A1 (an antioxidant 
enzyme) expression was inhibited to a lesser extent and corneal 
epithelial apoptosis was greatly attenuated. Therefore, in this 
model, topical trehalose effectively reduced oxidative damage 
of the   cornea evoked by ultraviolet B rays and protected against 
the development of an oxidative environment.
Trehalose use in humans
Trehalose is widely distributed in nature, including in 
many species that have long been incorporated into human 
  foodstuffs. Moreover, the finding that the human body has the 
trehalase enzyme (which cleaves one molecule of trehalose 
into two molecules of glucose) in cells of the intestinal villi 
and kidney brush border attest to the fact that humans have 
long been exposed to this disaccharide.
Trehalose is widely used as an ingredient in processed 
foodstuffs, is authorized in the European Union under Regu-
lation (EC) 258/97 (commission decision of 25 September 
2001), and is generally recognized as safe by the US Food 
and Drug Administration. The same year, the Joint Expert 
Committee on Food Additives (formed by the United Nations 
Food and Agriculture Organization and the World Health 
Organization), assessed the safety of trehalose and gave it a 
favorable evaluation.28
There are currently four injectable pharmaceutical prepa-
rations that contain trehalose as an excipient, ie, Avastin® 
and Herceptin® (Roche), Advate® (Baxter), and Lucentis® 
(Novartis), thus confirming that trehalose can be used safely 
as an ingredient in injectable formulations. Two of these 
preparations (Avastin and Lucentis) are administered to the 
human eye by intravitreal injection.
Trehalose is also an important component of Kyoto   solution. 
Recent studies suggest that the use of this preparation in the 
preservation of pancreatic tissue improves clinical outcomes in 
transplantation surgery.29 Although the relevant clinical studies 
are outside the scope of this review, trehalose has been shown 
to be more effective in improving objective signs of dry eye 
compared with hyaluronan and hydroxyethylcellulose solutions 
in patients with moderate or severe dry eye.30,31
Conclusion
Trehalose, a naturally occurring disaccharide, is widely 
distributed throughout the biological world and is found 
in plants, algae, fungi, yeasts, bacteria, insects, and other 
invertebrates, in which it plays a major role in anhydrobiosis, 
desiccation, and perhaps in the protection against   oxidative 
and other stresses. The mechanism by which trehalose 
provides such protection has not been fully elucidated, but 
probably involves stabilization of phospholipid bilayers and 
labile proteins, amongst other processes.
Figure  3  Rabbit  eyes  following  irradiation  with  ultraviolet  for  four  days,  with 
concurrent treatment of trehalose or buffered saline. A) Corneal vascularization 
and  loss  of  transparency  in  saline-treated  eye;  B)  and  C)  eyes  treated  with 
trehalose, showing less vascularization and retention of transparency; and D) normal 
(nonirradiated) cornea. 
Copyright© 2010. Histology and Histopathology. Reproduced with permission from 
Čejková J, Čejka Č, Ardan J, Širc J, Michálek J, Luyckx J. Reduced UVB-induced corneal 
damage caused by reactive oxygen and nitrogen species and decreased changes in 
corneal optics after trehalose treatment. Histol Histopathol. 2010;25:1403–1414.27Clinical Ophthalmology
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Although trehalose is not present in mammals, recent 
studies in cultured mammalian cells as well as ex vivo and 
in vivo studies show that trehalose can protect mammalian 
tissues from desiccation as well as oxidative stress. In par-
ticular, the findings of in vivo models of dry eye in mice 
or in ultraviolet B-induced keratitis in rabbits showing that 
topically applied trehalose can exert a significant protective 
effect on the ocular surface are notable. Trehalose is not a 
new entity in the pharmaceutical arena. It has already been 
used as an excipient in injectable protein drugs and is widely 
employed as a protector in freeze-dried oocytes for in vitro 
fertilization. These findings suggest that trehalose may be 
worthy of investigation as a potential agent for the protection 
of the ocular surface in dry eye syndrome in humans. The 
results of studies to date are encouraging.
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